UNSPSC 51262703: Tolazoline hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C10H12N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E669Z6S1JG, chemically known as 4,5-dihydro-2-(phenylmethyl)-1h-imidazole monohydrochloride but more generally known as tolazoline hydrochloride, which bears US NIH Compound Identifier 6048. European Medicines Agency schedules Tolazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04906MIG.

Most nations, for tariff and trade purposes, schedule tolazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, TOLAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolazoline hydrochloride bears US NLM identifiers UMLS ID C0770500 and NCI Concept Code C66609. SMILES: C1CCC(CC1)CC2=NCCN2.CL.

UNSPSC 51262703 Tolazoline hydrochloride is a Commodity code that in practice does not align with state and local procurement activity documented in recent solicitations. The code nominally describes a pharmaceutical compound used in veterinary and medical applications, but the one recent opportunity associated with it—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems for community health initiatives, a procurement unrelated to tolazoline hydrochloride itself. The mismatch suggests either a tagging error in the opportunity record or that this code does not reflect actual state and local purchasing patterns for the product it nominally describes.

The Seminole County solicitation, posted June 30, 2026 with a response deadline of July 26, 2023, seeks annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB requires electronic submission through the county's e-Procurement Portal, vendor drug-free workplace certification, E-Verify compliance, and specific insurance coverage. The contract runs for an initial two-year term with a one-year renewal option and includes a three-month probationary period. This single documented opportunity does not establish meaningful geographic spread or issuing-body concentration under the tolazoline hydrochloride code. Prospective vendors should verify code classification before pursuing work in this space, as the nominal code scope and actual state and local buying patterns appear disconnected.